Hexavalent vaccine antigens (DTaP-IPV-HB-Hib) (DTaP-IPV-HB-Hib)

Hexaxim bacterial and viral vaccine antigens comprise a combination of immunogenic substances designed to provide active immunity against six major pediatric infectious diseases. The bacterial components include purified diphtheria and tetanus toxoids, acellular pertussis antigens (pertussis toxoid and filamentous haemagglutinin), and the Haemophilus influenzae type b capsular polysaccharide conjugated to a tetanus protein carrier (EMA, 2023). The viral components consist of the hepatitis B surface antigen produced by recombinant DNA technology and inactivated poliovirus types 1, 2, and 3 (Sanofi, 2024). These antigens function by mimicking a natural infection to stimulate the production of specific antibodies and the development of memory B and T cells without causing the associated diseases (WHO, 2022). This hexavalent approach allows for simultaneous protection against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and invasive Hib infections, significantly reducing the number of injections required for infants. Clinical efficacy is typically monitored through seroconversion rates and the maintenance of protective antibody titers against each of the six components (PubMed, 2021).

Other names

Hexaxim antigensHexyon antigensHexacima antigens6-in-1 vaccine antigensDiphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b vaccine

Induction of active immunity through the stimulation of B and T lymphocytes to produce specific antibodies and establish long-term immunological memory against six pathogens (EMA, 2023; Sanofi, 2024).